Skip to main content
Skip to main content
Normal View Dyslexic View

Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.

Kato K, Machida R, Ito Y, Daiko H, Ozawa S, Ogata T et al, on behalf of the JCOG1109 investigators.
BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Lancet 2024; 404: 55-66.
This three-arm trial included 601 patients, with median follow-up 50.7 months. Three-year overall survival was highest after triplet chemotherapy including docetaxel (72.1 per cent), compared to doublet chemotherapy (62.6 per cent) and additional radiotherapy (68.3 per cent).
Comment: Triplet chemotherapy could be the new standard of care, but patients need to be robust.

Related articles


Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial.

Bang JY, Lakhtakia S, Thakkar S, Buxbaum JL, Waxman I, Sutton B et al, on behalf of the United States Pancreatic Disease Study Group.

16 August 2024

Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.

Labori KJ, Bratlie SO, Andersson B, Angelsen J-H, Biorserud C, Bjornsson B et al, for the Nordic Pancreatic Cancer Trial-1 study group.

30 August 2024
Copied!